Search Results

BACK FKSI-10 Languages Afrikaans Arabic Bengali Bosnian Bulgarian Cebuano Chinese - Simplified Chinese - Traditional Croatian Czech Danish Dutch English Estonian Finnish French German Greek Gujarati Hebrew Hindi Hungarian Italian Japanese Kannada Korean Latvian Lithuanian Malay Malayalam Marathi Norwegian Polish Portuguese Punjabi Romanian Russian Serbian Sesotho Slovak Spanish Swedish Tagalog Tamil Telugu Thai Turkish Ukrainian Urdu Vietnamese Xhosa Zulu

BACK FKSI-15 Languages Afrikaans Arabic Bengali Bosnian Bulgarian Cebuano Chinese - Simplified Chinese - Traditional Croatian Czech Danish Dutch English Estonian Finnish French German Greek Gujarati Hebrew Hindi Hungarian Italian Japanese Kannada Korean Latvian Lithuanian Malay Malayalam Marathi Norwegian Polish Portuguese Punjabi Romanian Russian Serbian Sesotho Slovak Spanish Swedish Tagalog Tamil Telugu Thai Turkish Ukrainian Urdu Vietnamese Xhosa Zulu

BACK FKSI-DRS Languages Afrikaans Arabic Bengali Bosnian Bulgarian Cebuano Chinese - Simplified Chinese - Traditional Croatian Czech Danish Dutch English Estonian Finnish French German Greek Gujarati Hebrew Hindi Hungarian Italian Japanese Kannada Korean Latvian Lithuanian Malay Malayalam Marathi Norwegian Polish Portuguese Punjabi Romanian Russian Serbian Sesotho Slovak Spanish Swedish Tagalog Tamil Telugu Thai Turkish Ukrainian Urdu Vietnamese Xhosa Zulu

BACK NFKSI-19 Languages Afrikaans Arabic Bengali Bosnian Bulgarian Cebuano Chinese - Simplified Chinese - Traditional Croatian Czech Danish Dutch English Estonian Finnish French German Greek Gujarati Hebrew Hindi Hungarian Italian Japanese Kannada Korean Latvian Lithuanian Malay Malayalam Marathi Norwegian Polish Portuguese Punjabi Romanian Russian Serbian Sesotho Slovak Spanish Swedish Tagalog Tamil Telugu Thai Turkish Ukrainian Urdu Vietnamese Xhosa Zulu

NFLSI-17 Functional Assessment of Cancer Therapy Lung Cancer Symptom Index – 17 Item Version For patients with Lung cancer; a FACT/NCCN-Lung Symptom Index LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The NCCN/FACT Lung Cancer Symptom Index-17 (NFLSI-17) is a brief symptom index for patients with advanced lung cancer. It was developed with input from 50 patients with advanced lung cancer who were recruited from National Comprehensive Cancer Network (NCCN) member institutions and community support agencies, along with 10 physician experts who were recruited from NCCN institutions. Patients reported symptoms associated with their disease in an open-ended format and then completed a checklist of symptoms, rating their 5 most important symptoms. Patient and provider ratings of symptom importance were tabulated to construct NFLSI-17. Patients also completed the Functional Assessment of Cancer Therapy-Lung (FACT-L), which was used to preliminarily validate the NFLSI-17. Based on this input, the NFLSI-17 is composed of 17 priority symptoms, 11 that are disease related, 3 that are treatment related, and 3 that are related to general functional well-being. Data on 15 of 17 NFLSI-17 symptoms showed good internal consistency (alpha = 0.74) and strong association with the FACT-L total and most subscale scores (r = 0.42-0.92). MEASURE NAME: Functional Assessment of Cancer Therapy Lung Cancer Symptom Index – 17 Item Version (NFLSI-17) VERSION: 2 NUMBER OF ITEMS: 17 PATIENT POPULATION: Lung cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Disease-Related Symptoms – Physical, Disease-Related Symptoms – Emotional, Treatment Side-Effects, Function/Well-Being TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores and total scores available. RELATED MEASURES: FACT-L , FLSI , FLSI-12 , FACT-LCS , FACT-PSI DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the NFLSI-17 can be obtained by registering for permission. Users are not permitted to translate the NFLSI-17 without permission from FACIT.org. Permission from FACIT.org to translate the NFLSI-17 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Cella, D., Paul, D., Yount, S., Winn, R., Chang, C-H, Banik, D., & Weeks, J. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation 2003; 21(4): 526-535. doi: 10.108/CNV-120022366. Cella, D., Rosenbloom, S., Beaumont, J., Yount, J., Paul, D., Hampton, D., Abernethy, A., Jacobsen, P., Syrjala, K., & Von Roenn, J. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. Journal of the National Comprehensive Cancer Network; 2011; 9(3): 268-278. doi: 10.6004/jnccn.2011.0026. Rosenbloom, S., Yount, S., Yost, K., Hampton, D., Paul, D., Abernethy, A., Jacobsen, P., Syrjala, K., Von Roenn, J., & Cella, D. Development and validation of eleven symptom indices to evaluate response to chemotherapy for advanced cancer: Measurement compliance with regulatory demands. Farquhar, I., Summers, K., Sorkin, A. (Eds.). The Value of Innovation: Impacts on Health, Life Quality and Regulatory Research. Emerald Group Publishing Inc. 2007; 16: 53-66. doi: 10.1016/S0194-3960(08)16003-6. Yount, S., Beaumont, J., Rosenbloom, S., Cella, D., Patel, J., Hensing, T., Jacobsen, P., Syrjala, K., & Abernethy, A. A brief symptom index for advanced lung cancer. Clinical Lung Cancer 2012; 13(1): 14-23. doi: 10.1016/j.cllc.2011.03.033. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-L Functional Assessment of Cancer Therapy – Lung LEARN MORE FLSI Functional Assessment of Cancer Therapy Lung Cancer Symptom Index - 6 Item Version LEARN MORE FLSI-12 Functional Assessment of Cancer Therapy Lung Cancer Symptom Index - 12 Item Version LEARN MORE

NFHNSI-22 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Head & Neck Cancer Symptom Index - 22 Item Version For patients with Head & Neck cancer; a FACT/NCCN-Head & Neck Symptom Index LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The NCCN/FACT Head & Neck Cancer Symptom Index-22 (NFHNSI-22) adequately reflects symptom and side effect concerns of advanced head & neck cancer patients as well as oncology physicians. Patients (N = 49) with advanced (Stages III and IV) head & neck cancers were recruited from participating National Comprehensive Cancer Network institutions and community cancer support organizations. Patients completed open-ended interviews and symptom checklists. Participating oncology physician experts also rated symptoms. Content validity was obtained by evaluating results alongside items in the FACIT system. Eleven oncologists categorized symptoms in terms of importance and whether the symptoms were primarily related to disease, treatment, or functional well-being. The NFHNSI-22 can be used to evaluate the most important disease-related symptoms, treatment side effects, and function/wellbeing in patients with advanced HCNs in clinical practice and research. MEASURE NAME: National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Head & Neck Cancer Symptom Index - 22 Item Version (NFHNSI-22) VERSION: 2 NUMBER OF ITEMS: 22 PATIENT POPULATION: Head & neck cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Disease-Related Symptoms – Physical, Disease-Related Symptoms – Emotional, Treatment Side Effects, Function/Well-Being TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores and total scores possible. RELATED MEASURES: FACT-HN , FHNSI , FACT-G DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the NFHNSI-22 can be obtained by registering for permission. Users are not permitted to translate the NFHNSI-22 without permission from FACIT.org. Permission from FACIT.org to translate the NFHNSI-22 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Cella, D., Paul, D., Yount, S., Winn, R., Chang, C-H, Banik, D., & Weeks, J. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation 2003; 21(4): 526-535. doi: 10.108/CNV-120022366. Cella, D., Rosenbloom, S., Beaumont, J., Yount, J., Paul, D., Hampton, D., Abernethy, A., Jacobsen, P., Syrjala, K., & Von Roenn, J. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. Journal of the National Comprehensive Cancer Network; 2011; 9(3): 268-278. doi: 10.6004/jnccn.2011.0026. Pearman, T., Beaumont, J., Paul, D., Abernethy, A., Jacobsen, P., Syrjala, K., von Roenn, J., & Cella, D. Evaluation of treatment and disease-related symptoms in advanced head and neck cancer: validation of the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy-Head and Neck cancer symptom index (NFHNSI-22). Journal of Pain and Symptom Management 2013; 46(1): 113-120. doi: 10.1016/j.jpainsymman.2012.06.004. Rosenbloom, S., Yount, S., Yost, K., Hampton, D., Paul, D., Abernethy, A., Jacobsen, P., Syrjala, K., Von Roenn, J., Cella, D. Development and validation of eleven symptom indices to evaluate response to chemotherapy for advanced cancer: Measurement compliance with regulatory demands. Farquhar, I., Summers, K., Sorkin, A. (Eds.). The Value of Innovation: Impacts on Health, Life Quality and Regulatory Research. Emerald Group Publishing Inc. 2007; 16: 53-66. doi: 10.1016/S0194-3960(08)16003-6. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-HN Functional Assessment of Cancer Therapy – Head & Neck LEARN MORE FHNSI Functional Assessment of Cancer Therapy Head & Neck Cancer Symptom Index - 10 Item Version LEARN MORE FACT-G Functional Assessment of Cancer Therapy – General LEARN MORE

NFHSI-18 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Hepatobiliary Cancer Symptom Index - 18 Item Version For patients with Hepatobiliary cancer (liver, bile duct and pancreas); a FACT/NCCN-Hepatobiliary Symptom Index LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The NCCN/FACT Hepatobiliary Cancer Symptom Index-18 assesses symptoms of importance to patients with hepatobiliary and pancreatic cancers and demonstrates promising measurement properties. The scale is a good candidate for brief symptom assessment in clinical trials. As part of a larger study in collaboration with the NCCN, 50 people (60% male, 80% Caucasian, average age 60.4 yrs) with Stage 3 or 4 hepatobiliary or pancreatic cancer were recruited. Participants generated and ranked up to 10 important symptoms and concerns that physicians should monitor when assessing the value of chemotherapy. Patients were also able to provide open-ended, qualitative information that was evaluated systematically. Ten expert physicians also provided input on priority symptoms. The resulting 18-item NFHSI (NFHSI-18) demonstrated high internal consistency (α = 0.89) and moderate to strong correlations with measures of physical well-being (ρ = 0.76), emotional well-being (ρ = 0.52), and functional well-being (ρ = 0.57). Scores were also highly correlated with the original hepatobiliary scale of the FACT-Hep (ρ =0.82; all p<0.001). Compared to patients with better performance status, patients with poor performance status had worse NFHSI-18 symptom scores, F (3, 47) = 9.74; p=0.0003. MEASURE NAME: National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Hepatobiliary Cancer Symptom Index - 18 Item Version (NFHSI-18) VERSION: 2 NUMBER OF ITEMS: 18 PATIENT POPULATION: Hepatobiliary cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Disease-Related Symptoms – Physical, Disease-Related Symptoms – Emotional, Treatment Side-Effects, Function/Well-Being TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores and total scores possible. RELATED MEASURES: FACT-Hep , FHSI , FACT-G DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the NFHSI-18 can be obtained by registering for permission. Users are not permitted to translate the NFHSI-18 without permission from FACIT.org. Permission from FACIT.org to translate the NFHSI-18 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Butt, Z., Parikh, N.D., Beaumont, J. L., Rosenbloom, S. K., Syrjala, K. L., Abernethy, A. P., Benson, A. B., & Cella, D. Development and validation of a symptom index for advanced hepatobiliary and pancreatic cancers: The NCCN-FACT Hepatobiliary-Pancreatic Symptom Index (NFHSI). Cancer 2012; 118(23): 5997-6004. Cella, D., Paul, D., Yount, S., Winn, R., Chang, C-H, Banik, D., & Weeks, J. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation 2003; 21(4): 526-535. doi: 10.108/CNV-120022366. Cella, D., Rosenbloom, S., Beaumont, J., Yount, J., Paul, D., Hampton, D., Abernethy, A., Jacobsen, P., Syrjala, K., & Von Roenn, J. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. Journal of the National Comprehensive Cancer Network; 2011; 9(3): 268-278. doi: 10.6004/jnccn.2011.0026. Rosenbloom, S., Yount, S., Yost, K., Hampton, D., Paul, D., Abernethy, A., Jacobsen, P., Syrjala, K., Von Roenn, J., Cella, D. Development and validation of eleven symptom indices to evaluate response to chemotherapy for advanced cancer: Measurement compliance with regulatory demands. Farquhar, I., Summers, K., Sorkin, A. (Eds.). The Value of Innovation: Impacts on Health, Life Quality and Regulatory Research. Emerald Group Publishing Inc. 2007; 16: 53-66. doi: 10.1016/S0194-3960(08)16003-6. Yount, S., Cella, D., Webster, K., Heffernan, N., Chang, C.-H., Odom, L., & van Gool, R. Assessment of patient-reported clinical outcome in Pancreatic and other Hepatobiliary Cancers: The FACT Hepatobiliary Symptom Index. Journal of Pain & Symptom Management 2002; 24(1), 32-44. doi: 10.1016/S0885-3924(02)00422-0. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-Hep Functional Assessment of Cancer Therapy – Hepatobiliary LEARN MORE FHSI Functional Assessment of Cancer Therapy Hepatobiliary Cancer Symptom Index - 8 Item Version LEARN MORE FACT-G Functional Assessment of Cancer Therapy – General LEARN MORE

NFBrSI-24 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Brain Cancer Symptom Index - 24 Item Version For patients with Brain cancer; A FACT/NCCN-Brain Symptom Index LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The NCCN-FACT Brain Symptom Index-24 (NFBrSI-24) is an index of the symptoms in advanced brain tumors perceived as most important by both patients and clinicians and improves upon existing measures of brain tumor symptoms through better satisfaction of regulatory requirements for measure development. The findings in development suggest good reliability and validity, indicating that the NFBrSI-24 is a promising brief assessment of high priority advanced brain tumor symptoms for research and clinical settings. MEASURE NAME: National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Brain Cancer Symptom Index - 24 Item Version (NFBrSI-24) VERSION: 2 NUMBER OF ITEMS: 24 PATIENT POPULATION: Brain cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Disease-Related Symptoms – Physical, Disease-Related Symptoms – Emotional, Treatment Side-Effects, Function/Well-Being TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores and total scores possible. RELATED MEASURES: FACT-Br , FBrSI , FACT-G DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the NFBrSI-24 can be obtained by registering for permission. Users are not permitted to translate the NFBrSI-24 without permission from FACIT.org. Permission from FACIT.org to translate the NFBrSI-24 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Cella, D., Paul, D., Yount, S., Winn, R., Chang, C-H, Banik, D., & Weeks, J. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation 2003; 21(4): 526-535. doi: 10.108/CNV-120022366. Cella, D., Rosenbloom, S., Beaumont, J., Yount, J., Paul, D., Hampton, D., Abernethy, A., Jacobsen, P., Syrjala, K., & Von Roenn, J. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. Journal of the National Comprehensive Cancer Network; 2011; 9(3): 268-278. doi: 10.6004/jnccn.2011.0026. Lai, J-S. Cella, D. Beaumont, J., Jensen, S. Development of a Symptom Index for Patients with Primary Brain Tumors. Value in Health 2014; 17: 62-69. doi: 10.1016/j.jval.2013.11.006. Rosenbloom, S., Yount, S., Yost, K., Hampton, D., Paul, D., Abernethy, A., Jacobsen, P., Syrjala, K., Von Roenn, J., & Cella, D. Development and validation of eleven symptom indices to evaluate response to chemotherapy for advanced cancer: Measurement compliance with regulatory demands. Farquhar, I., Summers, K., Sorkin, A. (Eds.). The Value of Innovation: Impacts on Health, Life Quality and Regulatory Research. Emerald Group Publishing Inc. 2007; 16: 53-66. doi: 10.1016/S0194-3960(08)16003-6. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-Br Functional Assessment of Cancer Therapy – Brain LEARN MORE FBrSI Functional Assessment of Cancer Therapy Brain Cancer Symptom Index - 15 Item Version LEARN MORE FACT-G Functional Assessment of Cancer Therapy – General LEARN MORE

BACK FACT-Br English Downloads Download PDF Download DOC

FACT-Br Functional Assessment of Cancer Therapy – Brain For patients with Brain cancer LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The Functional Assessment of Cancer Therapy – Brain is a valid measure of patients with brain cancer. In its development, 101 patients with primary brain tumors, after giving informed consent, participated in the last two phases of a four-phase validation process: item generation, item reduction, validation, and reliability testing. In the validation phase, FACT-G subscale and total scores as well as the brain subscale scores were correlated with other tests of mood, response, bias, and quality of life. Test-retest reliability testing was performed with 46 patients who had primary brain tumors. MEASURE NAME: Functional Assessment of Cancer Therapy – Brain (FACT-Br) VERSION: 4 NUMBER OF ITEMS: 50 PATIENT POPULATION: Brain cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Brain Cancer Subscale TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores and total scores possible. SAS/SPSS algorithms available RELATED MEASURES: FBrSI , NFBrSI-24 , FACT-G DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-Br can be obtained by registering for permission. Users are not permitted to translate the FACT-Br without permission from FACIT.org. Permission from FACIT.org to translate the FACT-Br may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Weitzner, M.A., Meyers, C.A., Gelke, C., Byrne, K., Cella, D.F., & Levin, V.A. The Functional Assessment of Cancer Therapy (FACT) Scale: Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 1995; 75(5): 1151-1161. Thavarajah, N., Bedard, G., Zhang, L., Cella, D., Beaumont, J., Tsao, M., Barnes, E., Danjoux, C., Sahgal, A., Soliman, H., & Chow, E. The Functional Assessment of Cancer Therapy – Brain (FACT-Br) for assessing quality of life in patients with brain metastases: A comparison of recall periods. Journal of Pain Management 2013; 6(3): 223-234. Thavarajah, N., G., Zhang, L., Cella, D., Beaumont, J. Tsao, M., Barnes, E., Danjoux, C., Sahgal, A., Soliman, H., & Chow, E. Psychometric validation of the functional assessment of cancer therapy—brain (FACT-Br) for assessing quality of life in patients with brain metastases Supportive Care in Cancer 2014; 22 (4): 1017-1028. doi: 10.1007/s00520-013-2060-8. Verhaak, E., Schimmel, W. C., Sitskoorn, M. M., Bakker, M., Hanssens, P. E., & Gehring, K. (2019). Multidimensional assessment of fatigue in patients with brain metastases before and after Gamma Knife radiosurgery. Journal of neuro-oncology , 144 (2), 377-384. Verhaak, E., Gehring, K., Hanssens, P. E., & Sitskoorn, M. M. (2019). Health-related quality of life of patients with brain metastases selected for stereotactic radiosurgery. Journal of neuro-oncology , 143 (3), 537-546. Verhaak, E., Schimmel, W. C., Gehring, K., Emons, W. H., Hanssens, P. E., & Sitskoorn, M. M. (2020). Health-related quality of life after Gamma Knife radiosurgery in patients with 1–10 brain metastases. Journal of Cancer Research and Clinical Oncology , 1-11. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FBrSI Functional Assessment of Cancer Therapy Brain Cancer Symptom Index - 15 Item Version LEARN MORE NRBrSI-24 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Brain Cancer Symptom Index - 24 Item Version LEARN MORE FACT-G Functional Assessment of Cancer Therapy – General LEARN MORE

BACK FACT-MM Languages Arabic Chinese – Simplified Czech Dutch English French German Greek Italian Portuguese Spanish

FACT-HN Functional Assessment of Cancer Therapy – Head & Neck For patients with Head & Neck cancer LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The Functional Assessment of Cancer Therapy – Head & Neck (FACT-H&N) is a reliable and valid measure for head and neck cancer patients, assessing unique disease specific concerns in addition to general health status. FACT-H&N subscale and total scores are sensitive to patient groups on the basis of treatment status (on vs. off treatment) and global performance status. The head & neck subscale includes 12 items on symptoms and issues specific to head and neck cancers, including ability to eat, dry mouth, difficulty breathing, difficulty swallowing, voice quality, ability to communicate, body image, pain in the mouth, throat, or neck, and alcohol and tobacco use. MEASURE NAME: Functional Assessment of Cancer Therapy – Head & Neck (FACT-HN) VERSION: 4 NUMBER OF ITEMS: 39 PATIENT POPULATION: Head & neck cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Head & Neck Cancer Subscale TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI scores possible. SAS/SPSS algorithms available. RELATED MEASURES: FHNSI , NFHNSI-22 , FACT-MBIS DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-HN can be obtained by registering for permission. Users are not permitted to translate the FACT-HN without permission from FACIT.org. Permission from FACIT.org to translate the FACT-HN may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References D'Antonio, L., Zimmerman G., Cella, D., & Long, S. Quality of life and functional status measures in patients with head and neck cancer. Archives of Otolaryngology-Head & Neck Surgery 1996; 122: 482-487. List, M.A., D'Antonio, L.L., Cella, D.F., Siston, A., Mumby, P., Haraf, D., & Vokes, E. The Performance Status Scale for Head and Neck Cancer (PSS-HN) and the Functional Assessment of Cancer Therapy-Head and Neck (FACT-H&N) Scale: A study of utility and validity. Cancer 1996; 77(11): 2294-2301. doi: 10.1002/(SICI)1097-0142(19960601)77:11<2294::AID-CNCR17>3.0.CO;2-S. Nayak SG, George A, Sharan K, Nayak BS, Ravishankar N. Effectiveness of Comprehensive Intervention Programme on Quality of life, fatigue, self-efficacy, and psychosocial distress among head and neck cancer patients receiving radiotherapy. Support Care Cancer . 2024 Mar 7;32(4):216. doi: 10.1007/s00520-024-08381-x. PMID: 38448712; PMCID: PMC10917822. Reeve, B., Cai, J., Zhang, H., Choi, J., Weissler, M., Cella, D., & Olshan, A. Health-related quality of life differences between African-Americans and Non-Hispanic whites with head and neck cancer. Head and Neck 2013; 35(9): 1255-64. doi: 10.1002/hed.23115. Ringash J, Lockwood G, O'Sullivan B, Warde P, Bayley A, Cummings B, Kim J, Sellmann S, & Waldron J. Hyperfractionated, accelerated radiotherapy for locally advanced head and neck cancer: quality of life in a prospective phase I/II trial. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology, 2008; 87(2):181-187. doi: 10.1016/j.radonc.2007.12.028. Ringash, J., Bernstein, L, Cella, D., Logemann, J., Movsas, B., Murphy, B., Trotti, A., Wells, N., Yueh, B., & Ridge, J. Outcomes toolbox for head and neck cancer research. Head & Neck 2015; 37(3): 425-39. doi: 10.1002/hed.23561. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FHNSI Functional Assessment of Cancer Therapy Head & Neck Cancer Symptom Index - 10 Item Version LEARN MORE NFHNSI-22 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Head & Neck Cancer Symptom Index - 22 Item Version LEARN MORE FACT-MBIS FACT/McGill Body Image Scale - Head & Neck LEARN MORE